Company Overview of Taiho Pharmaceutical Co., Ltd.
Taiho Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products. Its products include S-1, an oral antimetabolite and a combination of pharmacological compounds; ABI-007(Abraxane, a human serum albumin-bound paclitaxel; TSU-68, an orally administered, small-molecule, multiple receptor tyrosine kinase inhibitor; TAS-102, a novel combination antitumor agent; TAS-118, an antimetabolite solution; and ET-743(trabectedine), a synthetic derivative of a substance that was originally extracted from the colonial tunicate ecteinascidia turbinata. The company’s products also comprise TAS-114, an inhibitor of dUTPase, a gatekeeper protein in pyrimidine-metabolism; TAS...
Founded in 1963
Key Executives for Taiho Pharmaceutical Co., Ltd.
President and Representative Director
Chief Executive Officer of Otsuka Holdings Co., Ltd., President of Otsuka Holdings Co., Ltd. and Representative Director of Otsuka Holdings Co., Ltd.
Head of Production Division - Cmc Center and Director
Compensation as of Fiscal Year 2015.
Taiho Pharmaceutical Co., Ltd. Key Developments
Servier (France) Enters an Exclusive Licensing Agreement with Taiho
Jun 16 15
Servier (France) has entered an exclusive licensing agreement with Taiho (Japan) to develop the refractory metastatic colorectal cancer (mCRC) treatment TAS-102 (trifluridine + tipiracil hydrochloride) for commercialisation in European markets. The oral combination medicine has already received regulatory approval in Japan, where it was launched in 2014 under the brand name Lonsurf. The partnership deal means Taiho receives an upfront payment of USD 130 million from Servier, pending market authorisation approval in Europe, with provisos for further milestone payments and royalties linked to total net sales of the drug in European markets.
Taiho Pharmaceutical Co., Ltd. and Servier Enters into License Agreement for Development, Commercialization of Oral Anticancer Drug TAS-102 in Europe
Jun 15 15
Taiho Pharmaceutical Co., Ltd. and Servier announced on June 15, 2015 that they have entered into an exclusive license agreement on June 12, 2015 for the development and commercialization of TAS-102 in Europe and other countries. The company retains the right to develop and commercialize TAS-102 in the United States, Canada, Mexico and Japan/Asia and to manufacture and supply the product. TAS-102 is an oral combination anticancer drug initially developed by the company for use in the treatment of refractory metastatic colorectal cancer. Under this agreement, the company will receive a total of USD 130 million in an upfront payment and for MAA approval in the EU. In addition, the company will receive further regulatory and sales event milestone payments and royalties based on net sales. The company and Servier will also collaborate on the further global development of TAS-102 sharing effort and cost on an equal basis. The company and Servier anticipate that TAS-102, as a new treatment option, will make an even greater contribution to cancer patients in Europe and other countries through their partnership.
Taiho Pharmaceutical Co., Ltd. Announces Results from Global Phase III Trial of TAS-102
May 14 15
Taiho Pharmaceutical Co., Ltd. announced the publication of results from a global Phase III trial (RECOURSE) of TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride, brand name in Japan: "Lonsurf® combination tablet T15, T20") in the May 14 online issue of The New England Journal of Medicine?. TAS-102 is an oral combination anticancer drug intended for use in the treatment of refractory metastatic colorectal cancer (mCRC). The RECOURSE trial is a pivotal randomized, double blind, placebo controlled trial conducted in 800 mCRC patients, whose disease had progressed after or who were intolerant to standard therapies. This trial met the primary efficacy endpoint of statistically significant improvement in overall survival versus placebo (HR = 0.68, p < 0.001) and demonstrated a safety profile consistent with that observed in earlier clinical trials. TAS-102 is an oral combination investigational anticancer drug of trifluridine (FTD) and tipiracil hydrochloride (TPI). FTD is an antineoplastic nucleoside analog, which is incorporated into DNA, thereby interfering with the function of DNA. The blood concentration of FTD is maintained via TPI, which is an inhibitor of the FTD-degrading enzyme, thymidine phosphorylase.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|